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bjectives The goals of this analysis were: 1) to evaluate outcomes among non–ST-segment eleva-
ion myocardial infarction (NSTEMI) patients presenting to hospitals with on-site cardiac surgery
OHS hospitals) and without on-site cardiac surgery (No-OHS hospitals); and 2) to speciﬁcally exam-
ne outcomes among the subset of NSTEMI patients undergoing percutaneous coronary intervention
PCI).
ackground Whether backup cardiac surgery improves outcomes among NSTEMI patients or is sim-
ly a marker of better adherence to guideline recommendations is unknown.
ethods The NRMI (National Registry of Myocardial Infarction) enrolled 100,071 NSTEMI patients
rom 2004 to 2006. Outcomes were evaluated in the population as a whole and in propensity-
atched analyses in the entire population and in the subset of patients undergoing PCI.
esults In-hospital mortality was signiﬁcantly lower at OHS hospitals (5.0% vs. 8.8%, p  0.001).
atients presenting to OHS hospitals were signiﬁcantly more likely to receive aspirin, beta-blockers,
nd statins (p  0.05 for all) and to undergo PCI (38.4% vs. 14.1%, p  0.001). In the propensity-
atched model, the difference in mortality remained signiﬁcant (5.9% vs. 8.5%, p  0.001). After
djusting for differences in medications administered within 24 h of arrival and hospital characteris-
ics, the difference in mortality was nearly attenuated (hazard ratio: 0.89, 95% conﬁdence interval:
.79 to 1.00, p  0.050). When the propensity-matched model was restricted to patients undergoing
CI, there was no signiﬁcant difference in mortality (1.3% vs. 1.0%, p  0.51).
onclusions NSTEMI patients presenting to No-OHS hospitals have signiﬁcantly higher mortality.
his appears to be due to both modiﬁable (lower use of guideline-recommended medications) and
onmodiﬁable factors (hospital size, myocardial infarction volume). In a propensity-matched analysis
f patients undergoing PCI for NSTEMI, there was no signiﬁcant difference in mortality. (J Am Coll
ardiol Intv 2009;2:944–52) © 2009 by the American College of Cardiology Foundation
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945mong patients with non–ST-segment elevation myocar-
ial infarction (NSTEMI), early angiography and, if war-
anted, percutaneous coronary intervention (PCI) have been
ssociated with improved outcomes (1,2). An early invasive
trategy is therefore recommended among most patients
ith NSTEMI (3). As a result, cardiac catheterization in
STEMI patients is becoming more prevalent (4).
See page 953
Emergent cardiac surgery is sometimes required after
omplications from cardiac catheterization and PCI (5).
hile there is evidence that PCI performed among
STEMI patients at hospitals without on-site cardiac surgery
No-OHS hospitals) is safe (6), other studies have reported
igher mortality among patients undergoing PCI at No-OHS
ospitals (7). Elective PCI is currently not recommended at
ites without surgical backup in the American College of
ardiology/American Heart Association guidelines (3,8).
Surgical backup may improve outcomes because of its use after
omplications of PCI. Alternatively, it may simply be a marker of
uality of care and better adherence to guideline recommen-
ations. There were 2 goals of this analysis: 1) to compare
utcomes, the use of PCI, and the use of guideline-
ecommended medications among NSTEMI patients present-
ng to OHS and No-OHS hospitals; and 2) to compare
utcomes and the use of guideline-recommended medications
mong the subset of NSTEMI patients undergoing PCI at
ospitals with and without backup cardiac surgery. In order to
valuate these objectives, we utilized phase 5 of the NRMI
National Registry of Myocardial Infarction), which collected
ata from over 450 hospitals from 2004 to 2006.
ethods
RMI is an industry-sponsored observational study whose
ethods have previously been described (9,10). To be included
n the registry, patients must have had an acute myocardial
nfarction (MI) documented according to local hospital crite-
ia, usually including a history suggestive of acute MI and
orroborated by cardiac enzymes, 12-lead electrocardiogram
ECG), coronary angiography, or International Statistical
lassification of Diseases-9 diagnostic code of MI. NSTEMI
as defined as all patients enrolled who did not have ST-
egment elevation or left bundle branch block (old/new/
nknown) on first/subsequent 12-lead ECG.
A registry coordinator at each participating hospital
ecorded data from each patient, including demographic
nformation. In-hospital mortality was available among
atients who were not transferred to another facility.
To ensure quality control of registry data, registry coor-
inators were trained in data entry utilizing a standardized
anual of instructions and definitions. Case report forms
ere required to pass systematic range and internal consis- hency checking. Hospitals obtained approval of the registry
ata collection process as dictated by local investigational
eview boards.
Only hospitals with PCI capabilities were included in the
nalysis. In-hospital mortality, as well as the incidence of
ther adverse clinical outcomes, was assessed only among
atients who were not transferred as the outcome of patients
ransferred to other acute care hospitals was not known.
All statistical analyses were performed using a commer-
ially available statistical package (SAS 9.1.3 Service Pack 2,
AS Institute, Cary, North Carolina). Continuous variable
alues are reported as the mean plus or minus the standard
eviation or the median and interquartile range. Model-
ased approaches were used to analyze unmatched and
atched data. To account for clustering of patients within
ospitals, model-based group comparisons of binary, con-
inuous, and ordinal data were implemented using a gener-
lized estimating equations approach or generalized linear
ixed models. To estimate group differences in survival,
ox proportional hazard regres-
ion models for left-truncated
nd right-censored unmatched
ata were constructed, with and
ithout adjustment for propen-
ity score (as a continuous vari-
ble) and covariates. Treating
he transfer-in patient as the
runcating event and transfer-out,
eath, or discharge events as the
ensoring event, Cox regression
nalysis was applied to adjust
or differences in the administra-
ion of guideline-recommended
edications (aspirin, clopidogrel,
tatins, beta-blockers, and glyco-
rotein [GP] IIb/IIIa inhibitors) within 24 h, and hospital
haracteristics (region in U.S., hospital type, hospital size, and
I volume).
In the propensity-matched analysis, cases (patients pre-
enting to No-OHS hospitals) were matched to control
ubjects (patients presenting to OHS hospitals) using the
ropensity score generated from a nonparsimonious logistic
egression model. No interactions between the predictor
ariables were used in this model. In both total and PCI
atient populations, the C-statistic, or area under the
eceiver-operator characteristic curve, was 0.68, indicating
air discriminatory ability in predicting no-OHS. The
vents per variable statistic exceeded 10. A greedy matching
lgorithm was used to match patients based on 8¡1 digit
atching. Cases were matched to control subjects using the
ollowing set of independent variables: transferred-in status;
ex; age; hypertension; diabetes mellitus; hyperlipidemia;
troke; peripheral vascular disease; previous MI; congestive
Abbreviations
and Acronyms
CHF  congestive heart
failure
GP  glycoprotein
MI  myocardial infarction
No-OHS  hospitals without
on-site open heart surgery
NSTEMI  non–ST-segment
elevation myocardial
infarction
OHS  hospitals with on-site
open heart surgery
PCI  percutaneous
coronary interventioneart failure (CHF); smoking status; and aspirin, clopi-
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946ogrel, beta-blocker, and statin received within 24 h before
rrival. Patients grouped into control subjects were ran-
omly selected without replacement, and 97.5% of pairs had
xactly matching covariates. All p values used 2-tailed tests,
nd p values 0.05 were considered significant.
esults
here were 186,267 patients enrolled at 456 hospitals in the
RMI 5 registry from April 2004 to December 2006. Of
hese, 158,892 patients presented to 266 hospitals with PCI
apabilities. There were 100,071 NSTEMI patients: 9,189
9.2%) who presented to 52 No-OHS hospitals and 90,872
90.8%) who presented to 214 OHS hospitals. Baseline
haracteristics among the entire group are shown in Table 1
left). Patients presenting to OHS hospitals were slightly
ounger, more likely to be male, to have hyperlipidemia, to
resent with Killip class II, and to be receiving aspirin and less
ikely to have diabetes mellitus, hypertension, and a history of
eart failure. The most substantial difference between the
roups was that patients presenting to OHS hospitals were far
ore likely to have been transferred from another hospital
34.8% vs. 5.8%, p  0.001).
Patients presenting to OHS hospitals were significantly
ore likely to receive aspirin (87.8% vs. 84.0%, p  0.001),
eta-blockers (78.6% vs. 74.7%, p  0.014), and statins
44.3% vs. 38.0%, p  0.002) within 24 h after arrival
Table 2, left).
Patients presenting to OHS hospitals were more likely to
ndergo angiography (68.3% vs. 40.2%, p  0.001) and
CI (38.4% vs. 14.1%, p  0.001) (Table 3, left).
Patients who presented to No-OHS hospitals were much
ore likely to be transferred to another short-term general
ospital (35.3% vs. 2.2%, p  0.001). Baseline characteris-
ics among patients who were transferred out from No-
HS and those transferred in to OHS hospitals were
imilar, except that patients transferred out from No-OHS
ospitals had a slightly higher median body mass index (28.8
s. 28.3, p  0.023), were less likely Caucasian (81.8% vs.
7.9%, p  0.017), and have angina pectoris (8.9% vs. 15.0%,
 0.006), had a higher median pulse (84 vs. 80, p 0.001),
ystolic blood pressure (148 vs. 142, p  0.001), and diastolic
lood pressure (83 vs. 80, p  0.001).
Among patients who were not transferred (n  94,817),
n-hospital mortality was significantly lower among patients pre-
enting to OHS hospitals (5.0% vs. 8.8%, p  0.001) (Table 4,
eft). The incidence of recurrent MI was similar at the 2
ospital types (1.0% vs. 0.9%, p  0.64), but the incidence of
he composite of death and MI (5.8% vs. 9.5%, p 0.001) and
he composite of death, recurrent MI, CHF, and cardiogenic
hock (21.9% vs. 26.8%, p  0.043) was significantly lower
mong patients presenting to OHS hospitals.
Among patients who lived and were not transferred, there
ere significant differences favoring OHS hospitals in the ase of guideline-recommended discharge medications, in-
luding aspirin (89.6% vs. 81.2%, p  0.001), clopidogrel
55.9% vs. 46.9%, p  0.005), beta-blockers (86.3% vs.
0.5%, p 0.001), and statins (76.9% vs. 61.6%, p 0.001)
Table 5, left).
ropensity-matched analysis. Patients presenting to No-
HS hospitals were matched 1:1 in a propensity-matched
odel with patients presenting to OHS hospitals based on
he following baseline characteristics: transfer-in status; sex;
ge; hypertension; diabetes mellitus; hyperlipidemia; stroke;
eripheral vascular disease; previous MI; CHF; smoking
tatus; and aspirin, clopidogrel, beta-blocker, and statin
eceived within 24 h before arrival.
There were 9,049 patients in each group. Baseline char-
cteristics were similar between the groups and cross-strata
omparisons of covariates used in the propensity score
odels were nonsignificant (Table 1, center).
The differences in the administration of guideline-
ecommended medications favoring OHS hospitals was mildly
ttenuated in the propensity-matched analysis (Table 2, cen-
er), although patients presenting to OHS hospitals remained
ignificantly more likely to receive aspirin (87.5% vs. 84.2%,
 0.001), beta-blockers (78.5% vs. 75.1%, p  0.034), and
tatins (42.6% vs. 38.2%, p 0.038) in the first 24 h. The use
f GP IIb/IIIa inhibitors and angiotensin-converting enzyme
nhibitors or angiotensin receptor blockers was similar. OHS
ospitals were less likely to administer a heparin product
uring stay (70.9% vs. 74.0%, p  0.041).
More patients presenting to OHS hospitals underwent
ngiography (60.2% vs. 40.5%, p  0.001) and PCI (33.2%
s. 14.2%, p  0.001), and 10.6% of patients presenting to
HS hospitals in the propensity-matched analysis under-
ent coronary artery bypass grafting (Table 3, center).
There remained a large disparity in that patients present-
ng to OHS hospitals were far less likely to be transferred to
nother acute care hospital (2.7% vs. 35.4%, p  0.001).
mong patients who were not transferred, patients present-
ng to OHS hospitals had significantly lower in-hospital
ortality (5.9% vs. 8.5%, p  0.001) and had a lower
ncidence of the composite of death or MI (6.7% vs. 9.1%,
 0.001) (Table 4, center). The rates of recurrent MI,
HF, and cardiogenic shock were not significantly different
etween the 2 hospital types.
Among patients who lived and were not transferred, patients
ischarged from OHS hospitals were significantly more likely
o be prescribed aspirin (87.6% vs. 81.3%, p  0.001),
eta-blockers (85.5% vs. 80.6%, p 0.001), and statins (72.6%
s. 61.8%, p  0.001) (Table 5, center).
When this propensity-matched population was further
djusted for differences in the administration of aspirin,
lopidogrel, beta-blockers, statins, and GP IIb/IIIa inhibi-
ors within the first 24 h, and hospital region, type, size,
nd MI volume, the difference in mortality was largely
Table 1. Baseline Characteristics
Characteristic
Unmatched Patients Matched by Propensity Score Matched by Propensity Score, PCI Only
No-OHS
(n  9,199)
OHS
(n  90,872) p Value
No-OHS
(n  9,049)
OHS
(n  9,049) p Value
No-OHS
(n  1,282)
OHS
(n  1,282) p Value
Age, yrs, mean  SD* 69.5 13.9 68.5 13.3 0.039 69.5 13.9 69.4 13.8 0.70 63.5 12.9 63.5 12.7 0.93
Age, yrs, median (IQR)* 71 (58–81) 69 (58–80) 0.029 71 (58–81) 71 (58–81) 0.94 62 (53–74) 62 (53–73) 0.71
Male sex, %* 56.2 60.4 0.001 56.3 56.3 0.92 64.5 65.8 0.45
Caucasian, % 81.9 84.8 0.26 82.0 82.3 0.76 84.5 84.9 0.90
Weight, kg, mean  SD 82.1 22.5 82.9 21.7 0.15 82.1 22.5 81.4 21.8 0.15 87.2 20.7 86.5 20.2 0.47
Weight, kg, median (IQR) 80 (66–95) 81 (68–95.5) 0.14 80 (66–95) 79.5 (66–94) 0.46 85 (73–100) 85 (72–100) 0.65
Body mass index, mean  SD 28.6 7.0 28.7 6.7 0.66 28.6 7.0 28.5 6.7 0.26 29.7 6.5 29.5 6.2 0.49
Body mass index, median (IQR) 27.6 (24.0–32.3) 27.8 (24.3–32.0) 0.65 27.6 (24.0–32.3) 27.5 (24.0–31.9) 0.50 28.8 (25.4–33.2) 28.6 (25.4–33.3) 0.47
Medical history, %
Diabetes mellitus* 34.7 33.0 0.05 34.7 34.8 0.49 24.9 24.2 0.73
Hypertension* 70.2 68.5 0.039 70.3 70.1 0.85 65.9 66.1 0.94
Hyperlipidemia* 46.8 52.1 0.003 47.0 46.2 0.68 51.2 52.2 0.71
Current smoker* 27.8 28.4 0.68 27.8 27.3 0.74 38.6 37.4 0.64
Previous MI* 26.0 25.8 0.79 26.1 25.6 0.67 20.7 19.1 0.46
Previous PCI 16.9 18.2 0.14 17.0 16.6 0.70 17.6 18.4 0.64
CABG surgery 16.4 17.4 0.15 16.4 17.0 0.45 12.1 13.1 0.54
Stroke/CVA* 11.2 10.1 0.067 11.2 10.3 0.23 5.3 4.1 0.14
Peripheral vascular disease* 12.5 12.3 0.81 12.6 12.2 0.72 7.8 6.5 0.26
Chronic kidney disease 12.0 10.8 0.15 12.0 11.8 0.84 5.4 6.1 0.51
Atrial ﬁbrillation 11.2 9.5 0.027 11.1 10.4 0.40 4.4 5.4 0.27
Heart failure* 21.8 17.0 0.001 21.7 21.5 0.83 9.8 8.2 0.33
COPD 18.9 16.6 0.079 18.9 16.8 0.14 12.8 11.2 0.43
Medications 24 h pre-arrival
Aspirin* 37.4 42.0 0.11 37.3 37.4 0.97 37.4 38.5 0.81
Clopidogrel* 7.6 7.8 0.85 7.5 6.0 0.14 4.2 3.5 0.58
Beta-blocker* 23.5 25.6 0.49 23.5 23.0 0.87 16.1 16.9 0.81
Statin* 18.7 22.0 0.26 18.7 18.1 0.81 14.7 14.8 0.98
ACE inhibitor/ARB 18.3 18.5 0.90 18.3 17.9 0.89 12.5 14.1 0.55
Symptom onset-to-door time, % 0.77 0.77 0.35
2 h 21.1 20.5 21.1 20.5 27.1 23.8
2–4 h 10.9 11.0 10.9 11.2 12.2 11.9
4 h 15.1 17.4 15.2 17.2 19.6 21.5
Missing 52.9 51.2 52.7 51.1 41.1 42.8
Continued on next page
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Table 1. Continued
Characteristic
Unmatched Patients Matched by Propensity Score Matched by Propensity Score, PCI Only
No-OHS
(n  9,199)
OHS
(n  90,872) p Value
No-OHS
(n  9,049)
OHS
(n  9,049) p Value
No-OHS
(n  1,282)
OHS
(n  1,282) p Value
Arrival time, % n  9,097 n  83,172 0.47 n  8,949 n  8,925 0.63 n  1,249 n  1,231 0.10
Day (8 AM to 4 PM) 43.4 43.9 43.3 44.0 42.4 46.0
Evening (4 PM to 12 AM) 34.6 34.2 34.6 33.9 36.1 33.3
Night (12 AM to 8 AM) 22.0 21.9 22.0 22.1 21.5 20.7
Transferred-in, %* 5.8 34.8 0.001 5.9 5.9 1.00 15.2 15.2 1.00
Bed size, % 0.001 0.001 0.001
151 34.0 5.3 33.8 5.0 49.7 6.2
151–250 45.2 15.4 45.3 16.4 37.7 15.6
250 20.7 79.3 20.9 78.6 12.6 78.2
AMI volume, mean  SD 187.8 78.8 483.7 240.3 0.001 188.2 78.5 464.0 236.4 0.001 157.8 55.5 486.4 246.0 0.001
AMI volume, median (IQR) 184.9 (128.4–218.5) 466.5 (286.9–628.4) 0.001 180.7 (118.7–218.5) 417.7 (280.7–603.3) 0.001 170.2 (120.7–194.0) 473.8 (281.5–639.6) 0.001
Pulse, mean  SD 90.2 24.9 87.1 23.6 0.001 90.2 24.9 88.9 24.2 0.029 84.6 22.1 82.8 20.6 0.094
Pulse, median (IQR) 87 (73–104) 84 (70–100) 0.001 87 (73–103) 86 (72–101) 0.045 81 (70–96) 79.5 (68–93) 0.072
Systolic blood pressure, mm Hg, mean  SD 145.0 33.9 145.1 31.7 0.86 145.2 33.8 144.9 32.0 0.70 151.8 29.7 149.1 29.0 0.058
Systolic blood pressure, mm Hg, median (IQR) 144 (122–167) 144 (123–165) 0.44 144 (122–167) 144 (123–165) 0.93 150 (132–172) 147 (130–166) 0.035
Diastolic blood pressure, mm Hg, mean  SD 79.6 19.5 80.2 18.5 0.29 79.7 19.5 79.5 18.8 0.76 85.1 17.5 83.6 17.1 0.11
Diastolic blood pressure, mm Hg, median (IQR) 80 (67–93) 80 (68–92) 0.16 80.0 (67.0, 93.0) 80.0 (67.0, 92.0) 0.86 85.0 (74.0, 96.0) 84.0 (72.0, 95.0) 0.065
Creatinine, mg/dl, mean  SD 1.4 1.1 1.4 1.1 0.092 1.4 1.1 1.4 1.2 0.99 1.1 0.6 1.2 1.0 0.035
Creatinine, mg/dl, median (IQR) 1.1 (0.9–1.5) 1.1 (0.9–1.4) 0.009 1.1 (0.9–1.5) 1.1 (0.9–1.5) 0.40 1.0 (0.9–1.2) 1.0 (0.9–1.2) 0.55
Killip class, % n  9,195 n  90,683 0.001 n  9,045 n  9,047 0.28 n  1,279 n  1,280 0.001
No CHF 76.0 80.7 76.2 77.9 87.0 91.3
Rales, JVD 17.6 12.8 17.5 15.1 10.6 6.2
Pulmonary edema 5.8 5.8 5.8 6.1 2.1 2.4
Cardiogenic shock 0.6 0.7 0.6 0.8 0.3 0
*Predictor variables used in the propensity score model.
ACE angiotensin-converting enzyme; AMI acutemyocardial infarction; ARB angiotensin receptor blocker; CABG coronary artery bypass grafting; CHF congestive heart failure; COPD chronic obstructive pulmonary disease; CVA cerebrovascular accident;
IQR interquartile range; JVD jugular venous distension; MImyocardial infarction; No-OHS hospitals without on-site open heart surgery; OHS hospitals with on-site open heart surgery; PCI percutaneous coronary intervention.
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949ttenuated (hazard ratio: 0.89, 95% confidence interval:
.79 to 1.00, p  0.050) (Table 6).
ropensity-matched analysis, PCI patients. The propensity
atching was then restricted to patients who underwent
CI (n  1,282 in each group). Baseline characteristics,
edication use, and presenting characteristics were well
atched between the groups (Table 1, right). Patients
ndergoing PCI were substantially younger, more likely to
e men, less likely to have diabetes mellitus, hypertension,
rior coronary artery bypass grafting, stroke, chronic kidney
isease, atrial fibrillation, CHF, or chronic obstructive
ulmonary disease and were more likely to have hyperlip-
demia or be smokers than either the unmatched population
r entire propensity-matched population. They were also
ore likely to have been transferred in and generally had a
ower Killip class.
No-OHS hospitals were significantly more likely to admin-
ster clopidogrel (58.7% vs. 66.4%, p  0.001) and
ngiotensin-converting enzyme inhibitors or angiotensin re-
eptor blockers (37.8% vs. 44.5%, p  0.001) within the first
4 h (Table 2, right). The administration of aspirin, GP
Ib/IIIa inhibitors, beta-blockers, heparin products, and statins
ithin the first 24 h was similar at the 2 hospital types.
In-hospital mortality (1.3% vs. 1.0%, p  0.49); the
omposite of death and recurrent MI (2.0% vs. 1.1%,
 0.088); and the composite of death, recurrent MI,
ardiogenic shock, and CHF (9.4% vs. 8.6%, p  0.52)
Table 2. Medications Within 24 h After Arrival
Medication, %
Unmatched Patients
No-OHS
(n  9,199)
OHS
(n  90,872) p Value (n
Aspirin 84.0 87.8 0.001
Clopidogrel 35.7 40.0 0.17
Beta-blocker 74.6 78.6 0.014
GP IIb/IIIa inhibitor 27.5 32.0 0.065
UFH 31.9 37.7 0.13
LMWH 46.5 40.1 0.11
Any heparin during stay 73.7 72.1 0.27
ACE inhibitor/ARB 36.4 36.4 0.99
Statin 38.0 44.3 0.002
GP glycoprotein; LMWH low-molecular-weight heparin; UFH unfractionated heparin; other
Table 3. Interventional Strategies
Unmatche
No-OHS
(n  9,199) (n 
Coronary angiography, % 40.2
Elective percutaneous coronary intervention, % 14.1
CABG, % 0Abbreviations as in Table 1.mong patients undergoing PCI at OHS and No-OHS
ospitals was similar. Patients presenting to OHS hospitals
ho underwent PCI had a significantly higher incidence of
ecurrent MI (0.8% vs. 0.2%, p  0.041).
iscussion
atients with NSTEMI presenting to hospitals without
n-site cardiac surgery have significantly higher in-hospital
ortality than those presenting to hospitals with on-site
ardiac surgery. This difference was observed in both unad-
usted and propensity-matched models. However, the dif-
erence in mortality was of marginal significance after
djusting for both modifiable characteristics, such as the
dministration of guideline-recommended medications
ithin 24 h, as well as nonmodifiable characteristics, such as
ospital size, region, type, and MI volume. Furthermore, in
atients who underwent PCI at No-OHS hospitals, who
ere generally of better health than the population as a
hole, there was no increase in mortality when compared
ith similar patients undergoing PCI at OHS hospitals.
In addition to the difference in in-hospital outcomes
etween No-OHS and OHS hospitals, patients discharged
rom No-OHS hospitals were less likely to receive
uideline-recommended medications such as aspirin, beta-
lockers, and statins. Given the incremental possible benefit
erived from each of these medications (11–13), post-
tched by Propensity Score Matched by Propensity Score, PCI Only
S
49)
OHS
(n  9,049) p Value
No-OHS
(n  1,282)
OHS
(n  1,282) p Value
87.5 0.001 92.3 93.5 0.30
38.0 0.50 66.4 58.7 0.020
78.5 0.034 84.6 84.3 0.91
28.9 0.60 58.9 53.0 0.18
36.9 0.21 40.4 48.1 0.20
39.5 0.084 50.5 39.5 0.081
70.9 0.041 82.4 80.9 0.51
36.8 0.94 44.5 37.8 0.012
42.6 0.038 49.2 48.4 0.83
ations as in Table 1.
nts Matched by Propensity Score
2) p Value
No-OHS
(n  9,049)
OHS
(n  9,049) p Value
0.001 40.6 62.0 0.001
0.001 14.2 33.2 0.001
0.001 0 10.6 0.001Ma
No-OH
 9,0
84.2
35.8
75.1
27.6
32.0
46.6
74.0
36.6
38.2d Patie
OHS
90,87
68.3
38.4
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950ischarge adverse event rates may very well be increased
mong patients discharged from No-OHS hospitals.
This is the first study to specifically evaluate outcomes
mong patients with NSTEMI presenting to OHS and
o-OHS hospitals. Current guidelines recommend against
lective PCI at hospitals without surgical backup (8). This
ecommendation is based largely on a review of Medicare
ata by Wennberg et al. (7), who reported a 38% relative
Table 4. In-Hospital Clinical Outcomes
Outcome, %
Unmatched Patients
No-OHS
(n  5,949)
OHS
(n  88,868) p Value
Death 8.8 5.0 0.001
Recurrent MI 0.9 1.0 0.64
Death or recurrent MI 9.5 5.8 0.001
Death, recurrent MI, CHF, or
cardiogenic shock
26.8 21.9 0.043
CHF 19.5 17.5 0.44
Cardiogenic shock 3.0 3.1 0.83
Stroke 1.1 1.1 0.85
Bleeding requiring intervention 7.1 13.3 0.001
Related to CABG surgery 0 49.9 0.001
Transfusion required 81.3 88.5 0.010
New-onset atrial ﬁbrillation 5.9 7.6 0.025
Thrombocytopenia (20,000) 0.9 1.8 0.018
Target vessel revascularization 4.5 7.2 0.008
Intra-aortic balloon pump 1.0 3.9 0.001
Length of stay
Mean  SD 5.0 4.4 5.5 5.8 0.024
Median (IQR) 3.9 (2.5–6.1) 3.9 (2.4–6.8) 0.006
5 days 35.2 37.5 0.40
Transferred to another acute care
hospital
35.3 2.2 0.001
Ejection fraction, % 0.001
30 12.1 12.6
31–39 8.0 8.4
40–50 19.6 25.5
50 33.6 38.9
Not available 26.7 14.7
Abbreviations as in Table 1.
Table 5. Medications at Discharge
Medication, %
Unmatched Patients
No-OHS
(n  5,424)
OHS
(n  84,416) p Value
No-O
(n  5
Aspirin 81.2 89.6 0.001 81.
Clopidogrel 46.9 55.9 0.005 47.
Beta-blocker 80.5 86.3 0.001 80.
Statin 61.6 76.9 0.001 61.
ACE inhibitor/ARB 53.6 55.5 0.28 53.Abbreviations as in Table 1.ncrease in mortality among patients undergoing nonpri-
ary/rescue PCI at No-OHS hospitals after adjusting for
ifferences in baseline characteristics.
Other studies suggest that PCI in the setting of non–ST-
egment elevation acute coronary syndrome at hospitals without
urgical backup is safe and effective. In the Swedish Coronary
ngiography and Angioplasty registry, 16,245 patients with
STEMI or unstable angina underwent PCI at hospitals with
Matched by Propensity Score Matched by Propensity Score, PCI Only
-OHS
5,842)
OHS
(n  8,809) p Value
No-OHS
(n  1,237)
OHS
(n  1,276) p Value
8.5 5.9 0.001 1.0 1.3 0.51
0.8 1.0 0.50 0.2 0.8 0.047
9.1 6.7 0.001 1.1 2.0 0.11
6.5 25.3 0.63 8.6 9.4 0.62
9.6 20.4 0.78 6.5 7.8 0.37
2.9 3.3 0.40 2.2 1.6 0.52
1.1 1.2 0.45 0.4 0.2 0.42
7.0 13.4 0.001 4.4 6.6 0.020
0 45.8 0.001 0 7.1 0.001
1.7 89.2 0.014 81.8 83.3 0.83
5.9 7.7 0.023 2.9 3.4 0.59
0.9 1.8 0.017 0.6 1.4 0.16
4.5 6.7 0.029 5.7 7.2 0.40
1.0 3.5 0.001 1.8 2.0 0.71
 4.5 5.8 5.5 00.001 3.9 2.8 4.0 3.4 0.70
.5–6.1) 4.1 (2.7–7.0) 0.001 3.0 (2.2–4.5) 3.0 (2.1–4.4) 0.68
5.0 40.7 0.045 20.6 19.0 0.62
5.4 2.7 0.001 3.5 0.5 0.001
0.002 0.63
2.1 13.1 7.7 7.1
8.1 8.1 7.7 5.7
9.7 25.3 27.5 28.2
3.8 37.6 46.4 48.9
6.3 15.8 10.6 10.1
ed by Propensity Score Matched by Propensity Score, PCI Only
OHS
(n  8,293) p Value
No-OHS
(n  1,225)
OHS
(n  1,260) p Value
87.6 0.001 95.5 96.1 0.60
51.9 0.14 84.5 85.6 0.63
85.5 0.001 90.8 89.6 0.48
72.6 0.001 83.5 86.4 0.27
54.5 0.69 63.8 61.5 0.43No
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951n  12,073) and without (n  4,172) backup cardiac surgery
14). The 30-day mortality (1.0% vs. 1.2%) was not significantly
ifferent between the groups. In a study of patients presenting to
single No-OHS and OHS hospital, there were no deaths or
ecurrent MIs at either hospital type among the 104 patients who
ad NSTEMI (6).
The findings presented here suggest that efforts aimed at
ncreasing adherence to guideline recommendations at No-
HS hospitals appear to be warranted and may help close
he gap in mortality between the 2 hospital types. Such
mprovements in adherence are not only within reach, but,
hen achieved at No-OHS hospitals, are associated with
mproved outcomes. As noted in the propensity-matched
nalysis, among low-risk PCI patients, No-OHS hospitals
tilized guidelines-based therapies more often, and, in turn,
his was associated with a significantly lower incidence of
ecurrent MI.
Larger hospital size and higher volume have been asso-
iated with improved outcomes among patients undergoing
CI (15–17). Many of these studies did not discriminate
etween truly elective PCI and PCI in the setting of
STEMI or unstable angina. The findings in the current
nalysis provide further evidence that hospital characteristics
lay a significant role in outcomes among patients with
STEMI, and that outcomes at smaller hospitals with
ower MI volumes are significantly worse.
tudy limitations. There are several limitations to the cur-
ent study. While many hospitals participated in the NRMI
egistry, these hospitals may not be representative of all health
are facilities, and they likely reflect larger, more procedure-
riented centers. There was no independent validation of
ata forms. The outcomes of patients who were transferred
o other hospitals are unknown. Long-term outcomes are
ot known. The American College of Cardiology/American
eart Association guidelines for the management of pa-
ients with NSTEMI were updated in 2007. Although all of
he medications listed in the current analysis had class I
ndications in the 2004 guidelines, it is possible that the
e-emphasis of an update to the guidelines has increased the
se of these medications at hospitals without backup cardiac
urgery. Medication treatment may be a function of living
Table 6. Multivariate Model Among Propensity Score-Matched Patients*
Adjustment Hazard Ratio 95% CI p Value
None 0.70 0.64–0.77 0.001
Medications within 24 h† 0.81 0.74–0.89 0.001
Above  hospital characteristics‡ 0.89 0.79–1.00 0.050
*Treating the transfer-in patient as the truncating event and transfer-out, death, or discharge
events as the censoring event; †aspirin, clopidogrel, glycoprotein IIb/IIIa inhibitors, lipid-
lowering agents, beta-blockerswithin 24 h after arrival;‡region, teaching hospital, urban setting,
size, volume of myocardial infarctions.
CI confidence interval.ong enough to receive medications, rather than the thera-ies alone. In addition, the added model components may
imply reflect the hospital type, such that the significance of
ospital type drops as the new variables are added.
onclusions
atients with NSTEMI presenting to hospitals without
ackup cardiac surgery have significantly higher in-hospital
ortality, even after adjusting for differences in baseline
atient characteristics. The difference in mortality appears
o be the result of both modifiable and nonmodifiable
actors, suggesting that efforts to increase adherence to
uideline recommendations are warranted. Among the rel-
tively healthy cohort of patients who underwent PCI at
ospitals without on-site cardiac surgery, there was no
ncrease in mortality compared with similar patients at
ospitals with backup cardiac surgery.
eprint requests and correspondence: Dr. C. Michael Gibson,
50 Longwood Avenue, 1st Floor, Boston Massachusetts 02115.
-mail: mgibson@perfuse.org.
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